Nile Pharmaceuticals results, Q4 2022
Net profit, assets, equity and cash flow for Q4 2022, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit89.67 millionEGP
Total assets769 millionEGP
Shareholders' equity431 millionEGP
Operating cash flow4.91 millionEGP
In short
- Nile Pharmaceuticals's net profit for Q4 2022 was about 89.67 million EGP.
- Total assets at the end of Q4 2022 were about 769 million EGP, and shareholders' equity about 431 million EGP.
- Operating cash flow for Q4 2022 was positive at 4.91 million EGP.
Key lines against the same period a year earlier
This periodYear earlierChange
Net profit89.67 million——
Gross profit535 million——
Total assets769 million——
Total liabilities339 million——
Shareholders' equity431 million——
Total liabilities and equity769 million——
Operating cash flow4.91 million——
Investing cash flow-48 million——
Financing cash flow-12.62 million——
Net change in cash-55.71 million——
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Nile Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy